JERUSALEM , May 31, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NETC) (TASE: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the upcoming Jefferies 2018 Healthcare Conference taking place June 5 - 8, 2018 in New York City . Jeffrey A.

More than 350 patients enrolled in pivotal Phase 3 ACCORDANCE trial and more than 80% of eligible patients entered the open label extension study JERUSALEM , May 15, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) (" Intec " or "the Company") today announces financial results for

JERUSALEM, April 24, 2018 /PRNewswire/ -- Intec Pharma LTD (NASDAQ, TASE:NTEC) ("Intec" or "the Company") today announces that data collected from two Phase 1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease were highlighted in a poster presentation at

Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares JERUSALEM, April 13, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of 6.75 million of its ordinary shares, at a public offering price

JERUSALEM, April 11, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of 6.75 million of its ordinary shares at a public offering price of $5.25 per ordinary share. The gross proceeds of the offering are expected to be

JERUSALEM, April 10, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) today announced the launch of an underwritten public offering of its ordinary shares. In connection with this offering, Intec Pharma also intends to grant the underwriters a 30-day option to purchase up to an

JERUSALEM, April 4, 2018 /PRNewswire/ -- Intec Pharma LTD (NASDAQ: NTEC) (TASE: NTEC) ("Intec" or "the Company") today announces that data collected from the Company's Phase 2 development program of its proprietary Accordion Pill™ oral drug delivery system have been accepted for poster presentation

JERUSALEM, April 3, 2018 /PRNewswire/ -- Intec Pharma Ltd . (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary  Accordion Pill™  platform technology, today announced it will host a Key Opinion Leader (KOL)

JERUSALEM, March 26, 2018 /PRNewswire/ -- Intec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Directors. Dr. Pomerantz is President, Chief Executive Officer and Chairman of the Board of Directors of

Global leader in formulation and film technology manufacture to establish commercial scale production capabilities for Intec's lead product candidate in FDA compliant facility JERUSALEM, March 12, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC) ("Intec" or the "Company") today announces